Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Roche_Pharma
|
| gptkbp:acquisition |
gptkb:Genentech
gptkb:TIB_Molbiol gptkb:Flatiron_Health gptkb:Spark_Therapeutics gptkb:Foundation_Medicine |
| gptkbp:awards |
Innovation Award
Best Workplaces Top Employer Europe |
| gptkbp:ceo |
gptkb:Severin_Schwan
|
| gptkbp:clinical_trial |
collaborates with hospitals
collaborates with universities collaborates with research institutions focus on personalized medicine focus on patient-centric trials conducts globally focus on drug development focus on biomarker discovery |
| gptkbp:employees |
around 100,000
|
| gptkbp:focus |
neurology
oncology rare diseases infectious diseases immunology |
| gptkbp:founded |
gptkb:1896
|
| gptkbp:founder |
gptkb:Fritz_Hoffmann-La_Roche
|
| gptkbp:global_presence |
strong in Latin America
strong in Europe strong in North America strong in Asia strong in Africa |
| gptkbp:headquarters |
gptkb:Basel,_Switzerland
|
| https://www.w3.org/2000/01/rdf-schema#label |
Roche Pharma AG
|
| gptkbp:industry |
gptkb:drug
|
| gptkbp:market |
diagnostic tests
prescription medications |
| gptkbp:operates_in |
over 100 countries
|
| gptkbp:partnership |
gptkb:temple
gptkb:Sanofi gptkb:Pfizer gptkb:Novartis |
| gptkbp:philanthropy |
gptkb:Roche_Global_Health_Initiative
Roche Access Program Roche Community Fund Roche Patient Foundation |
| gptkbp:products |
biopharmaceuticals
diagnostics |
| gptkbp:research_and_development |
high investment
|
| gptkbp:revenue |
58.3 billion CHF (2020)
|
| gptkbp:stock_exchange |
gptkb:SIX_Swiss_Exchange
|
| gptkbp:subsidiary |
gptkb:Roche_Diagnostics
|
| gptkbp:sustainability |
diversity and inclusion initiatives
committed to environmental responsibility focus on access to healthcare |
| gptkbp:symbol |
gptkb:ROG
|